This is topic ELTP- GONNA BURST ON NEWS in forum .11 and Up! at Allstocks.com's Bulletin Board.


To visit this topic, use this URL:
http://www.allstocks.com/stockmessageboard/ubb/ultimatebb.php/ubb/get_topic/f/16/t/001425.html

Posted by CAPTNEMOS on :
 
WAS TOLD TO GRAB SOME THIS AM.WINK WINK
 
Posted by CAPTNEMOS on :
 
.235 wow and still gaining.theres was news yesterday.that was supposed to be released today.


Elite Pharmaceuticals Announces First Shipment of Generic Phentermine HCl Tablets
Apr. 7, 2011 (GlobeNewswire) --
NORTHVALE, N.J., April 7, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that the initial shipment of phentermine HCl 37.5 mg tablets, the generic version of Adipex-P® 37.5 mg tablets, was made, triggering a milestone payment under the License, Manufacturing and Supply Agreement with Precision Dose and its wholly owned subsidiary TAGI Pharma, Inc. TAGI Pharma will distribute the product as part of a multi-product distribution agreement.

Phentermine HCl is a member of the amphetamine and phenethylamine class. It is an appetite suppressant used to help reduce weight in obese patients when used short-term and combined with exercise, diet, and behavioral modification.

For the most recent twelve months ending December 2010, Adipex-P® and its generics had total U.S. sales of approximately $40 million according to IMS Health Data.

About TAGI Pharma, Inc.

TAGI Pharma was launched by Precision Dose in 2010 as a specialty pharmaceutical company focused on the Retail Market Segment. A key component of TAGI Pharma's strategy is the leveraging of its sales and distribution core competencies with the formation of strategic partnerships that have product development and manufacturing capabilities such as Elite. The phentermine HCl 37.5 mg product represents the first of these initiatives, and we expect an additional six product launches in the next six months. As the company sources products through development, acquisition and licensing opportunities, key areas of focus will be in the tablet, capsule and injectable dosage formats, with an emphasis on controlled substances, where there are additional barriers to entry. TAGI Pharma is located in South Beloit, Illinois, and additional information can be obtained from its website www.tagipharma.com.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Two of Elite's products, Lodrane 24® and Lodrane 24D®, are marketed by a partner, ECR Pharmaceuticals, for allergy treatment. Elite's lead pipeline products are novel sustained release oral formulations of oxycodone for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Both products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are in late-stage development. Elite, with partners, also has an ANDA filed with the FDA for a generic equivalent of a pain product and has a generic gastrointestinal drug product in clinical development. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

The Elite Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8737

This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. Elite undertakes no obligation to update any forward-looking statements.

CONTACT: For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
 
Posted by CAPTNEMOS on :
 
nice rebound after another block added to my portfolio.
 
Posted by narbeh on :
 
hey CAPTNEMOS, or anyone else, still holding this? I bought in at the dip around $.125. making a nice bounce, hopefully it keeps rolling.
 
Posted by narbeh on :
 
another pullback, guess its time to buy more haha
 
Posted by CAPTNEMOS on :
 
quote:
Originally posted by narbeh:
hey CAPTNEMOS, or anyone else, still holding this? I bought in at the dip around $.125. making a nice bounce, hopefully it keeps rolling.

yes im still holding a large block.waiting on next 10q should be anyday now.last 10q they did awesome.showed profit for first time.also waiting on announcement about the european release.they have three approved generic drungs there connected with also.which had no effect on previous 10q.so i think theres gonna be alot of news and another great 10q filing.this is only my and only my speculation. [Good Luck]
 
Posted by CAPTNEMOS on :
 
people and websites are all over snss(sunesis pharm)1 of the most hyped and pumped stocks.and there at $2.55 i think.and there books sucked and they dont have near as many approved generic products.so at these levels looks like a great opportunity to buy.
 
Posted by narbeh on :
 
good stuff, hopefully I can buy some more in the AM or before that news pops.
 
Posted by CAPTNEMOS on :
 
24-May-2011

Other Events, Financial Statements and Exhibits


Item 8.01 Other Events.
On May 24, 2011 the Company issued a press release announcing that all of the outstanding shares of its Series D 8% Convertible Preferred Stock (the "Series D") has been converted into the Company's common stock, pursuant to the Amended Certificate of Designations of the Series D 8% Convertible Preferred Stock as filed with the Secretary of State of the State of Delaware on June 29, 2010. The Series D conversion thereby eliminates the Company's obligations to pay $720,000 in annual dividends and eliminates the administrative costs associated therewith.

A copy of the press release, dated May 24, 2011, is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.


Item 9.01 Financial Statements and Exhibits
a) Not applicable.
b) Not applicable.
c) Not applicable.
d) Exhibits

Exhibit No. Exhibit

99.1 Press Release dated May 24, 2011

means they save a ton of money,but theres more supply of common stock now.which in turn if theres no buyers gobbling them up .price will drop.this one is a hold.
 
Posted by CAPTNEMOS on :
 
awful lot of stock changing hands.been a ton of insider activity.hmmm.
 
Posted by CAPTNEMOS on :
 
THE FRIGGIN FDA BANNED 2 OF THERE SHORT TERM MONEY MAKERS


Northvale, New Jersey, Friday, March 04, 2011: Northvale, NJ – March 4, 2011: Elite Pharmaceuticals, Inc. (OTC:BB: ELTP) advises that the US Food and Drug Administration (FDA) announced that it intends to remove approximately 500 cough/cold and allergy related products from the U.S. market. Elite currently manufactures two of the drugs impacted by the FDA’s action which are marketed by ECR Pharmaceuticals, a wholly owned subsidiary of Hi-Tech Pharmacal, Co., Inc. The affected products are:

Product Active Ingredient, Strength
Lodrane® 24 capsules brompheniramine maleate, 12mg
Lodrane® 24 D capsules brompheniramine maleate, 12 mg/
pseudoephedrine HCl, 90mg

According to the FDA press release, manufacturers must stop manufacturing the affected products within 90 days after March 3, 2011 and must stop shipping these products within 180 days after March 3, 2011.

In addition to receiving revenues for the manufacture and contract laboratory services of these products, Elite receives a royalty on in-market sales from ECR Pharmaceuticals. Revenues generated from these products totaled $3.02 million for the 9 months ended December 31, 2010, representing substantially all of Elite’s revenues for the period. The Company’s inability to manufacture these drugs could have an adverse effect on its revenues.

As disclosed by Hi-Tech Pharmacal, ECR Pharmaceutical initiated in 2010 a formal approval process with the FDA regarding Lodrane® 24 and Lodrane® 24D and ECR will continue to actively pursue approval for both products.
About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and manufactures oral, controlled-release products using proprietary technology. Elite's strategy includes the development of life cycle management products to lengthen the franchise life of drug products facing patent expiration, the development of controlled-release formulations of existing products to improve their clinical profile, the development of abuse-resistant opioids to mitigate misuse of these drugs, and the development of generic versions of controlled-release brand drug products with high barriers to entry. Elite developed and manufactures for its partner, ECR Pharmaceuticals, Lodrane 24® and Lodrane 24D®, a non-sedating antihistamine for the treatment of allergy symptoms. As previously disclosed in SEC filings, the company recently purchased, and expects to soon launch three approved generic products. In addition, Elite has a pipeline of additional generic and branded drug candidates under active development. Two of the branded products under active development are ELI-216, an abuse resistant oxycodone product, and ELI-154, a once-a-day oxycodone product. Elite conducts research, development and manufacturing in its facility in Northvale, New Jersey.

WHY I THINK WAS A BIG DROP BACK IN MAR.DONT KNOW HOW IT WILL EFFECT NEXT 10Q,DUE TO THE FACT THEY HAVE 3 PRODUCTS ARE READY TO BE LAUNCHED ANY DAY NOW.
 
Posted by CAPTNEMOS on :
 
Product Pipeline

Programs Under Development

Branded Products (a)

Therapeutic Category

NDA / ANDA

Development Stage (b)

Partnered

ELI-154
Oxycodone CR
Once a day
NA

Pain

NDA

Phase III pending

No

ELI-216
Abuse Resistance Product for use with oxycodone or other opioids
N/A

Pain

NDA

Phase III pending

No

Undisclosed
Twice a day
Undisclosed

Anti-infective

ANDA

Pilot BE study complete

No

Undisclosed
Once a day
Undisclosed

Gastrointestinal

ANDA

Pilot BE study complete

Yes


Commercial Products

Commercial
Product

Branded Products (a)

Therapeutic Category

Commercial
Status

Partner

Lodrane®
Once a Day
N/A

Allergy

Launched

ECR Pharmaceuticals

Lodrane 24D ®
Once a day
N/A

Allergy

Launched

ECR Pharmaceuticals

Methadone Hydrochloride
10 mg tablets Dolophine®
hydrochloride, 10 mg tablets Pain FDA Approved, Launch pending
ThePharmaNetwork

Hydromorphone Hydrochloride
8 mg tablets Dilaudid®
8 mg Pain FDA Approved, Launch pending Precision Dose, Inc.
Naltrexone Hydrochloride
50 mg ReVia® and Depade® Opioid Receptor Antagonist FDA Approved, Launch pending Precision Dose, Inc.
 
Posted by CAPTNEMOS on :
 
One look at the resume of Elite Pharmaceuticals, Inc. (OTCBB: ELTP) and it’s hard to understand how the specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations is trading around the 0.0595 and 0.0600 mark yet despite its impressive pipeline of products and some valuable technology related to control release pharmaceutical products the company is where they are and many investors are jumping on the stock with thoughts of a big payday in the not too distant future.
Of course when shares are trading at such a low level there is usually a reason and ELTP has certainly run into a few roadblocks over the past year. Most recently the company learned that the FDA intends to remove approximately 500 cough/cold allergy related products from the U.S market and ELTP manufactures a pair of the drugs, marketed by ECR Pharmaceuticals (a wholly owned subsidiary of Hi-Tech Pharmacal, Co, Inc.), that are subject for removal.
As part of the FDA decision ELTP must stop manufacturing both Lodrane 24 capsules and Lodrane 24D capsules within 90 days after March 3 and those products cannot be shipped after 180 days after March 3, 2011. This would seem like devastating news for ELTP due in large part to the fact the revenue generated for the nine-month period ending on Dec. 31, 2010, was almost all generated by the Lodrane products. According to their most recent quarterly report the nine-month period generated revenues of $3,052,864 of which $3.02 million came from the soon to be pulled drugs.
Perhaps even more frustrating for investors is the fact the third quarter figures restored a sense of hope as the company showed an operating profit of $72,931 compared to an operating loss of $509,893 for the same period last year. Making the profit all the more significant was the fact it was the first time the company had achieved such a milestone. Now it looks like the FDA is ready to prevent ELTP from two consecutive quarters of profitability.
That being said ELTP does have a bit of time to play with having been given three months to essentially manufacture as much of the allergy symptom relief remedy as they can and the products can ship for an additional three months past the manufacturing deadline. This grace period could allow for the company to generate some additional revenues while they continue their efforts on other projects.
Among the other projects is their active development of ELI-216, an abuse resistant oxycodone product, and ELI-154, a once-a-day oxycodone product, both of which could generate substantial revenue for ELTP as a pain management therapy. ELTP has been in discussions to license its once daily oxycodone product, ELI-154, to a European marketing partner while scaling up the development of ELI-216. ELTP has retained the rights to these two products but has said “they expect to license these products at a later date to a third party who could provide funding for the remaining clinical studies, including a Phase III study, and who could provide sales and distribution for the product.”
Just last month ELTP announced the FDA approval of an Abbreviated New Drug Application (ANDA) for phentermine HCl 37.5 mg tablets. The phentermine HCl tablets are the generic equivalent of the Adipex-P(R) 37.5 mg tablets. In September of last year ELTP acquired the ANDA for the generic product from Epic Pharma LLC and with a licensing agreement and a manufacturing and supply agreement in place with Precision Dose, Inc., whose wholly owned subsidiary TAGI Pharma, Inc. will distribute the product, ELTP now climbs into a market that generated about $40 million in sales in 2010. As part of the licensing agreement ELTP will receive a milestone payment as well as receive a percentage of the gross profit as a result of sales of the products.
Again, it’s hard to see all the positive things tied to ELTP and not wonder how the share price could be so low. Even the bad news surrounding Lodrane shouldn’t be enough to cause investors to turn a blind eye, especially because the drugs marketer, Hi-Tech Pharmacal, remains determined to gain FDA approval for both of the products being pulled from the shelves.
As it stands shares are just slightly above the 50-day moving average of 0.0509 and 200-day moving average of 0.0568 but over the next few months as their pipeline develops, they anticipate launching at least three more generic products in the near future, their pps could climb significantly.
What has been most intriguing about ELTP has been the relative coolness of the new management which has kept their cards close to their vest. Nobody would ever accuse the company of pushing out frivolous press releases or publishing meaningless numbers, they have remained rather quiet and that could be a sign that they are actually concentrating on following through with their plans for development. They’ve managed to cut operating costs, trim down the staff, and control spending and now it looks as if their vision is within reach.
Who’s to say where ELTP will be in a year but judging by how they have handled adversity and continue to push forward don’t be surpri
 
Posted by CAPTNEMOS on :
 
New Change Ahead for Biopharmaceuticals -- Insight on Elite Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.
Jun. 1, 2011 (Marketwire) --

BEIJING -- (Marketwire) -- 06/01/11 -- Today, www.GlobalEquityReporter.com announced its research report highlighting Elite Pharmaceuticals, Inc. (OTCBB: ELTP) and Taro Pharmaceutical Industries Ltd. (PINKSHEETS: TAROF). Full report download is available at www.GlobalEquityReporter.com/access.php.

Biotech is enabling creation of new drugs at a faster pace than the traditional pharmaceutical model and some believe that after a decade of mediocre performance it is approaching an inflection point. Companies are much more conducive to focusing on productivity and the sector is showing signs of being back to top growth by 2013 due to the opportunity emerging markets have created.

Global Equity is reporting on Elite Pharmaceuticals, Inc. for its position as a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, using technology. The Company has two products: Lodrane 24 and Lodrane 24D, being sold commercially. It also has an approved generic methadone product developed with its partner. The PharmaNetwork. Elite manufactures two once-daily allergy products, Lodrane 24 and Lodrane 24D, that were co-developed with its partner, ECR Pharmaceuticals (ECR). The full report and profile on Elite Pharmaceuticals, Inc. (OTCBB: ELTP) is available here: www.GlobalEquityReporter.com/get.PDF.1824.php.

Global Equity Reporter brings Taro Pharmaceutical Industries to light for its focus on developing, manufacturing and marketing prescription and over-the-counter (OTC) pharmaceutical products primarily in the United States, Canada and Israel. It also develops and manufactures active pharmaceutical ingredients (APIs) primarily for use in its finished dosage form products. Its primary areas of focus include topical creams and ointments, liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The full report and profile on Taro Pharmaceutical Industries Ltd. (PINKSHEETS: TAROF) is available here: www.GlobalEquityReporter.com/get.PDF.1937.php.

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research -- providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers. We report potential market opportunity to our members before the same situation grows to become strong market momentum, enabling our members to see strong market growth by delivering information before the crowd.

Contact:

Alexander Griffin
Email Contact
www.GlobalEquityReporter.com


Source: Marketwire (June 1, 2011 - 9:02 AM EDT)
 
Posted by CAPTNEMOS on :
 
entry-286,000 shares @.14c avg
est hold-6-18 months
my target $.49c-$2.(will take 30-40%profit/w inital investment and hold free shares for 2-4 years.or until bought out).

1 of their drugs alone could make them a heavy hitter,let alone 3 approved for release.i think on the way its going.she will explode once they release some nice sales figures on some of those.and the current ban on the 2 of theirs isnt an istant.they can pump out as much as they want up until approx june,and then commercial sales is in end of Aug.by then they will be rocking the three others and they have in pipeline i think like 8 more working thru clinical stages.And a bunch more planned.gonna be huge.
 
Posted by CAPTNEMOS on :
 
got this in my email early this morning from Diane(investor relations)


ELITE PHARMACEUTICALS ANNOUNCES RECLASSIFICATION OF SUPPLEMENT APPLICATION WITH FDA
NORTHVALE, N.J. - June 6, 2011 - Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that on May 31, 2011, it had been notified by the US Food and Drug Administration (FDA) that its Change Being Affected in 30 Days ("CBE 30") supplement for the manufacturing and packaging of Hydromorphone Hydrochloride USP 8 mg had been reclassified requiring its prior approval, which may result in a delay in the products commercialization.
About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has one approved and commercial ANDA product partnered with TAGI Pharma, with an additional three ANDAs currently under review by the FDA. Elite's lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale , NJ .

This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. Elite undertakes no obligation to update any forward-looking statements.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
 
Posted by CAPTNEMOS on :
 
ELITE PHARMACEUTICALS ANNOUNCES MANUFACTURING AND SUPPLY AGREEMENT WITH MIKAH PHARMA, LLC


NORTHVALE, N.J. - June 6, 2011 - Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that it has entered into a commercial Manufacturing and Supply Agreement with Mikah Pharma, LLC ("Mikah"). Under the terms of the agreement, Elite will perform the laboratory stability studies, manufacturing and packaging for two generic products: Isradipine Capsules USP, 2.5 mg and 5 mg and Phendimetrazine Tartrate Tablets USP, 35 mg.

Elite will be compensated at an agreed upon transfer price for the manufacturing and packaging of the products. For the Isradipine product, Elite will receive a 10% royalty on net profits of the finished products. Elite will also receive a onetime milestone payment for each product for the work associated with the technology transfer.

"The Mikah agreement represents Elite's continuing progress in utilizing our manufacturing infrastructure and expertise to generate revenues," commented Jerry Treppel, Chairman and CEO.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has one approved and commercial ANDA product partnered with TAGI Pharma, with an additional three ANDAs currently under review by the FDA. Elite's lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale , NJ .

This news release contains forward-looking statements, including those related to the preliminary nature of the clinical program results and the potential for further product development, that involve known and unknown risks, delays, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of the companies to be materially different from the results, performance or other expectations implied by these forward-looking statements. In particular, because substantial future testing will be required prior to approval, the results described above may not be supported by additional data or by the results of subsequent trials. These risks and other factors, including the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, and intellectual property protections and defenses, are discussed in Elite's filings with the Securities and Exchange Commission such as the 10K, 10Q and 8K reports. Elite undertakes no obligation to update any forward-looking statements.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
 
Posted by CAPTNEMOS on :
 
almost .20c.nice gains.
 
Posted by CAPTNEMOS on :
 
ELITE PHARMACEUTICALS ANNOUNCES MANUFACTURING AND SUPPLY AGREEMENT WITH THEPHARMANETWORK , LLC
NORTHVALE, N.J. - June 29, 2011 - Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that it has entered into a commercial Manufacturing and Supply Agreement with ThePharmaNetwork, LLC, and its wholly owned subsidiary, Ascend Laboratories, LLC (together "TPN"). Under the terms of the agreement, Elite will perform manufacturing and packaging for TPN's Methadone Hydrochloride, 10 mg tablets .

Elite will be compensated at an agreed upon price for the manufacturing and packaging of the products.

Jerry Treppel, Chairman and CEO of Elite commented, "We are pleased to assist TPN with the launch and commercialization of their Methadone product and in light of the recent action by the FDA with the Lodrane family of products, this agreement will help Elite buffer the impact by providing a new revenue stream."
 
Posted by theman on :
 
Do you think it is a good time to buy back in?
 
Posted by CAPTNEMOS on :
 
they only dropped because of earnings,they reinvested alot of the earnings back into research and development,so most people didnt see that ,they saw the final number of them losing money.thats what i think,im holding,youll see.ton of drugs coming out,so its only up.and when it dropped,i scooped up a ton more shares.upto 846,000 shares at an avg of .125.im looking fer 25-46c soon.
 
Posted by CAPTNEMOS on :
 
im out at .15C.nice coin
 
Posted by CAPTNEMOS on :
 
quote:
Originally posted by CAPTNEMOS:
they only dropped because of earnings,they reinvested alot of the earnings back into research and development,so most people didnt see that ,they saw the final number of them losing money.thats what i think,im holding,youll see.ton of drugs coming out,so its only up.and when it dropped,i scooped up a ton more shares.upto 846,000 shares at an avg of .125.im looking fer 25-46c soon.

Your full of crap as always Capt.lol.
 


© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2